KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Consolidated Net Income (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Consolidated Net Income data on record, last reported at $844.6 million in Q4 2025.

  • For Q4 2025, Consolidated Net Income fell 7.97% year-over-year to $844.6 million; the TTM value through Dec 2025 reached $4.5 billion, up 2.09%, while the annual FY2025 figure was $4.5 billion, 2.09% up from the prior year.
  • Consolidated Net Income reached $844.6 million in Q4 2025 per REGN's latest filing, down from $1.5 billion in the prior quarter.
  • Across five years, Consolidated Net Income topped out at $3.1 billion in Q2 2021 and bottomed at -$1.5 billion in Q4 2022.
  • Average Consolidated Net Income over 5 years is $1.1 billion, with a median of $1.0 billion recorded in 2023.
  • Peak YoY movement for Consolidated Net Income: skyrocketed 245.36% in 2021, then plummeted 72.5% in 2022.
  • A 5-year view of Consolidated Net Income shows it stood at $1.8 billion in 2021, then crashed by 183.01% to -$1.5 billion in 2022, then skyrocketed by 176.9% to $1.2 billion in 2023, then decreased by 20.86% to $917.7 million in 2024, then dropped by 7.97% to $844.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Consolidated Net Income were $844.6 million in Q4 2025, $1.5 billion in Q3 2025, and $1.4 billion in Q2 2025.